Please use this identifier to cite or link to this item:
http://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2615
Title: | A shortened treatment with rosemary tea (rosmarinus officinalis) instead of glucose in patients with diabetes mellitus type 2 (TSD) |
Authors: | Quirarte Báez, Sol María Zamora Perez, Ana Lourdes Reyes Estrada, Claudia Araceli Gutiérrez Hernández, Rosalinda Sosa Macías, Martha Galaviz Hernández, Carlos Guerrero Manriquez, Gloria Guillermina Lazaldo Ramos, Blanca Patricia |
Issue Date: | 3-Dec-2019 |
Publisher: | Research Trentz |
Abstract: | Background Rosemary leaves powder has been reported to reduce in a dose-dependent manner, glucose levels, lipid profile and lipid peroxidation in humans. However, patients should ingest high doses of powder contained in capsules. This formulation constitutes the intake of 10 capsules per day, so the active metabolite must first, be released and then absorbed (for which, rosemary leaf powder must be mixed with gastric juice). Aim Evaluate whether a shortened dose and time of treatment as well as the pharmaceutical presentation in rosemary tea (Rosmarinus officinalis) instead of powder have a therapeutic effect in the treatment of T2D. Method The complementary therapy with Rosemary tea (2g/1 litre of water per day) were evaluate on resistance to insulin, oxidative stress, biochemical parameters and anthropometric measurements in forty patients T2D under treatment with metformin and/or glibenclamide afther giving your authorization through informed consent. |
URI: | http://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2615 https://doi.org/10.48779/vg31-3k15 |
ISSN: | 2561-8741 |
Other Identifiers: | info:eu-repo/semantics/publishedVersion |
Appears in Collections: | *Documentos Académicos*-- M. en Ciencias y Tecnología Química |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
A shortened treatment with rosemary tea (rosmarinus officinalis) instead of.pdf | 749,29 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License